$0.89
+0.07 (+8.42%)
Open$0.84
Previous Close$0.83
Day High$0.90
Day Low$0.83
52W High$7.30
52W Low$3.70
Volume—
Avg Volume134.0K
Market Cap60.08M
P/E Ratio56.26
EPS$0.10
SectorBiotechnology
Analyst Ratings
Strong Buy
14 analysts
Price Target
+570.5% upside
Current
$0.89
$0.89
Target
$6.00
$6.00
$4.29
$6.00 avg
$7.91
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 9.23M | 9.01M | 7.68M |
| Net Income | -678,125 | -522,642 | -466,092 |
| Profit Margin | -7.4% | -5.8% | -6.1% |
| EBITDA | -963,511 | -904,753 | -762,039 |
| Free Cash Flow | -508,030 | -465,093 | -442,494 |
| Rev Growth | +6.0% | +24.9% | +0.1% |
| Debt/Equity | 0.23 | 0.22 | 0.21 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |